Found­ing NewLink CEO Charles Link is out; Chi-Med lines up two more drug fil­ings

Four years ago NewLink’s shares were rid­ing high on the promise of IDO in on­col­o­gy, trad­ing at more than $50 a share …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.